FDA Warns Hospira Over Issues At Costa Rican Plant

Law360, New York (August 28, 2012, 7:26 PM EDT) -- Hospira Inc. disclosed on Tuesday that it has received a warning letter from the U.S. Food and Drug Administration regarding quality issues uncovered during an inspection of a Costa Rican facility at which most of the company's infusion devices and sets are manufactured.

In a report filed Tuesday with the U.S. Securities and Exchange Commission, the device maker said it had received a letter on Aug. 23 citing numerous issues at its La Aurora de Heredia, Costa Rica, device manufacturing facility, though it noted that the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.